@kaulcsmc @gcfmd @JavedButler1 @texhern @DCRINews Therapy for myocardial infarction, both PCIand medical, has improved so much that it is very difficult to show the efficacy of any intervention We demonstrated that SGLT2i improve remodeling in postMI pigs
RT @ApoThera: Postulated Effect of #Empagliflozin on Heart Failure https://t.co/OnTw1lJZG1 #HeartFailure #MedEd #MedTwitter #cardiovascular…
RT @ApoThera: Postulated Effect of #Empagliflozin on Heart Failure https://t.co/OnTw1lJZG1 #HeartFailure #MedEd #MedTwitter #cardiovascular…
RT @ApoThera: Postulated Effect of #Empagliflozin on Heart Failure https://t.co/OnTw1lJZG1 #HeartFailure #MedEd #MedTwitter #cardiovascular…
RT @ApoThera: Postulated Effect of #Empagliflozin on Heart Failure https://t.co/OnTw1lJZG1 #HeartFailure #MedEd #MedTwitter #cardiovascular…
RT @ApoThera: Postulated Effect of #Empagliflozin on Heart Failure https://t.co/OnTw1lJZG1 #HeartFailure #MedEd #MedTwitter #cardiovascular…
RT @ApoThera: Postulated Effect of #Empagliflozin on Heart Failure https://t.co/OnTw1lJZG1 #HeartFailure #MedEd #MedTwitter #cardiovascular…
RT @ApoThera: Postulated Effect of #Empagliflozin on Heart Failure https://t.co/OnTw1lJZG1 #HeartFailure #MedEd #MedTwitter #cardiovascular…
RT @ApoThera: Postulated Effect of #Empagliflozin on Heart Failure https://t.co/OnTw1lJZG1 #HeartFailure #MedEd #MedTwitter #cardiovascular…
Postulated Effect of #Empagliflozin on Heart Failure https://t.co/OnTw1lJZG1 #HeartFailure #MedEd #MedTwitter #cardiovascular #CardioTwitter #Cardiology #TwitteRx #PharmaTwitter #Bioinformatics #usmlestep1 #USMLE #USMLESTEP3 #internalmedicine #primarycare
RT @cardiomet_CE: 9) Our friend & #SoMe education advocate @SantosGallegoMD holds: #SGLT2 inhibitors are efficacious for #heartfailure inde…
RT @cardiomet_CE: 9) Our friend & #SoMe education advocate @SantosGallegoMD holds: #SGLT2 inhibitors are efficacious for #heartfailure inde…
9) Our friend & #SoMe education advocate @SantosGallegoMD holds: #SGLT2 inhibitors are efficacious for #heartfailure independently of #LVEF See 🔓https://t.co/C602ZrpggN
RT @ckd_ce: 9) Our friend & #SoMe education advocate @SantosGallegoMD holds: #SGLT2 inhibitors are efficacious for #heartfailure independen…
9) Our friend & #SoMe education advocate @SantosGallegoMD holds: #SGLT2 inhibitors are efficacious for #heartfailure independently of #LVEF See 🔓https://t.co/Ozokk6bzeC
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics https://t.co/bUtBhxfoiP https://t.co/MfWe1eiCnQ
RT @SantosGallegoMD: @mvaduganathan @Iatrus84 @cardiomet_CE @matthewmylee @MassarOmard Completely agree about the importance of myocardial…
RT @SantosGallegoMD: @mvaduganathan @Iatrus84 @cardiomet_CE @matthewmylee @MassarOmard Completely agree about the importance of myocardial…
@mvaduganathan @Iatrus84 @cardiomet_CE @matthewmylee @MassarOmard Completely agree about the importance of myocardial energetics. Increased ATP production has been demonstrated for HFrEF in pig (yours truly) & rat (@salvareverentia), and for HFpEF in i
@HanCardiomd @JavedButler1 Not surprising at all given 1) benefits on MACE and HF, 2) diuretic effect, 3) improvement on LV subclinical dysfunction, 4) previous data about BNP reductions with empa and cana https://t.co/ig63o6dSPv https://t.co/0E5iPI2d7Y
@Nephro_Sparks @KSusztak @kidney_boy It would be simplistic to think SGlT2i only have one mechanism: switch in energetic metabolism from Glc to FFA, NHE inhibition, activation of SIRT, autophagy, antiinflammatory (inflammasome inhibition), activation of HI
@ChristosArgyrop @ethanjweiss @mikejohansenmd @hswapnil Do you mean SGLT2i improving myocardial energetics? As in this elegant pig experiment by @SantosGallegoMD and @RequenaIbanez? Or in EMPA-VISION trial (endpoint PCr/ATP)? https://t.co/w6XqYKanih htt
@ChristosArgyrop SGLT2i improve energetics in the heart! (And probably in the kidney). Now the question is whether this is a cause or a consequence of ammeliorating HF https://t.co/0E5iPI2d7Y https://t.co/NLzOdgiNX6
@adnan_haider1 This are also interesting articles about #SGLT2i https://t.co/w6XqYKanih https://t.co/0YGynBeCzk https://t.co/HLevGwCSgi
@MayooranShan @ProfDFrancis HF improvement will result in less diuretic dose However, the mechanism of action is not only diuresis. Also 1) NHE inhibition, and 2) metabolic switch in utilization of fuel from glucose to fatty acid and ketones, which impro
Empagliflozin switches myocardial fuel utilization away from energy inefficient glucose towards consumption of fatty acids and ketone bodies, which improve myocardial energetics. Novel mechanism! https://t.co/zUxFog6Ghh
Imaging techniques demonstrate that the SGLT2 inhibitor empagliflozin improves heart failure and ameliorates adverse LV remodeling even in non-diabetic models! Very comprehensive study using both cardiac MRI and 3D-echocardiography https://t.co/zUxFog6Ghh
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @Virgilio_Cadete: Are ketones the answer to HF? Is glucose metabolism overrated in HF? Empagliflozin Ameliorates Adverse Left Ventricu…
Are ketones the answer to HF? Is glucose metabolism overrated in HF? Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondi... https://t.co/TOZ97GVCEz
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…
RT @ValleAlfonso: Empagliflozin ⤵️ adverse cardiac remodeling and HF in a nondiabetic porcine model. Empagliflozin improving myocardial ene…
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondi... https://t.co/UEDsU06GEp
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @ketonemics: Empagliflozin Ameliorates Adverse LV Remodeling in Nondiabetic HF by Enhancing Myocardial Energetics -Empa increases ketone…
RT @FUNDAPROCECA: La cuarta era de la DMT2: Cardiodiabetologia https://t.co/F7uDOBOG1J
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @FUNDAPROCECA: La cuarta era de la DMT2: Cardiodiabetologia https://t.co/F7uDOBOG1J
La cuarta era de la DMT2: Cardiodiabetologia
RT @ValleAlfonso: Empagliflozin ⤵️ adverse cardiac remodeling and HF in a nondiabetic porcine model. Empagliflozin improving myocardial ene…
La empagliflozina podría revertir la insuficiencia cardiaca (JACC) Investigadores de la Escuela de Medicina Icahn en Mount Sinai (Estados Unidos) han demostrado que la empagliflozina, un fármaco antidiabético recientemente... https://t.co/AdxTmkUh3j
RT @ValleAlfonso: Empagliflozin ⤵️ adverse cardiac remodeling and HF in a nondiabetic porcine model. Empagliflozin improving myocardial ene…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…
RT @mbotana: 3.- Ayuda a explicar la diferencia de morbimortalidad CV entre los estudios con iSGLT2 que incluyen más población en prevenció…
RT @ketonemics: Empagliflozin Ameliorates Adverse LV Remodeling in Nondiabetic HF by Enhancing Myocardial Energetics -Empa increases ketone…
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics https://t.co/u6kiqxL2IN
RT @bassbarajas: Efecto de los SGLT-2 a 2 meses sobre remodelado cardiaco en modelo animal. La historia de los SGLT-2 y su posible relació…
RT @HeartDocSadiya: Growing evidence that SGLT2i should be considered a HF drug rather than a DM drug. https://t.co/abeGCFQME6
RT @HeartDocSadiya: Growing evidence that SGLT2i should be considered a HF drug rather than a DM drug. https://t.co/abeGCFQME6
RT @JACCJournals: Empagliflozin ameliorates adverse ventricular remodeling in non-diabetic heart failure by enhancing myocardial energetics…
RT @HeartDocSadiya: Growing evidence that SGLT2i should be considered a HF drug rather than a DM drug. https://t.co/abeGCFQME6
RT @HeartDocSadiya: Growing evidence that SGLT2i should be considered a HF drug rather than a DM drug. https://t.co/abeGCFQME6
RT @JACCJournals: Empagliflozin ameliorates adverse ventricular remodeling in non-diabetic heart failure by enhancing myocardial energetics…
RT @JACCJournals: Empagliflozin ameliorates adverse ventricular remodeling in non-diabetic heart failure by enhancing myocardial energetics…
RT @JACCJournals: Empagliflozin ameliorates adverse ventricular remodeling in non-diabetic heart failure by enhancing myocardial energetics…
RT @JACCJournals: Empagliflozin ameliorates adverse ventricular remodeling in non-diabetic heart failure by enhancing myocardial energetics…
RT @JACCJournals: Empagliflozin ameliorates adverse ventricular remodeling in non-diabetic heart failure by enhancing myocardial energetics…
Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energetics | JACC: Journal of the American College of Cardiology https://t.co/yB3zmITL94
RT @mbotana: 3.- Ayuda a explicar la diferencia de morbimortalidad CV entre los estudios con iSGLT2 que incluyen más población en prevenció…
RT @JACCJournals: Empagliflozin ameliorates adverse ventricular remodeling in non-diabetic heart failure by enhancing myocardial energetics…
RT @MarkNBMD: Another week, another promising trial for #SGLT2 inhibitors in heart failure https://t.co/uhykFQsQ5j
RT @HeartDocSadiya: Growing evidence that SGLT2i should be considered a HF drug rather than a DM drug. https://t.co/abeGCFQME6
RT @MarkNBMD: Another week, another promising trial for #SGLT2 inhibitors in heart failure https://t.co/uhykFQsQ5j
Another week, another promising trial for #SGLT2 inhibitors in heart failure
RT @JACCJournals: Empagliflozin ameliorates adverse ventricular remodeling in non-diabetic heart failure by enhancing myocardial energetics…
RT @JACCJournals: Empagliflozin ameliorates adverse ventricular remodeling in non-diabetic heart failure by enhancing myocardial energetics…
RT @ValleAlfonso: Empagliflozin ⤵️ adverse cardiac remodeling and HF in a nondiabetic porcine model. Empagliflozin improving myocardial ene…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…
RT @JACCJournals: Empagliflozin ameliorates adverse ventricular remodeling in non-diabetic heart failure by enhancing myocardial energetics…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…
RT @JACCJournals: Empagliflozin ameliorates adverse ventricular remodeling in non-diabetic heart failure by enhancing myocardial energetics…
Growing evidence that SGLT2i should be considered a HF drug rather than a DM drug.
@MichaelNassifMD @boback @gcfmd Empagliflozin ameliorates adverse ventricular remodeling in NON-diabetic heart failure by enhancing myocardial energetics. https://t.co/xgUZU5W12B #JACC
@aishaikh @RenalFellowNtwk One more piece to the puzzle of SGLT2i and CV benefits Empagliflozin ameliorates adverse ventricular remodeling in non-diabetic heart failure by enhancing myocardial energetics. https://t.co/xgUZU5W12B #JACC
RT @JACCJournals: Empagliflozin ameliorates adverse ventricular remodeling in non-diabetic heart failure by enhancing myocardial energetics…
RT @JACCJournals: Empagliflozin ameliorates adverse ventricular remodeling in non-diabetic heart failure by enhancing myocardial energetics…
RT @JACCJournals: Empagliflozin ameliorates adverse ventricular remodeling in non-diabetic heart failure by enhancing myocardial energetics…
RT @JACCJournals: Empagliflozin ameliorates adverse ventricular remodeling in non-diabetic heart failure by enhancing myocardial energetics…
RT @JACCJournals: Empagliflozin ameliorates adverse ventricular remodeling in non-diabetic heart failure by enhancing myocardial energetics…
RT @JACCJournals: Empagliflozin ameliorates adverse ventricular remodeling in non-diabetic heart failure by enhancing myocardial energetics…
RT @JACCJournals: Empagliflozin ameliorates adverse ventricular remodeling in non-diabetic heart failure by enhancing myocardial energetics…
RT @ValleAlfonso: Empagliflozin ⤵️ adverse cardiac remodeling and HF in a nondiabetic porcine model. Empagliflozin improving myocardial ene…
RT @JACCJournals: Empagliflozin ameliorates adverse ventricular remodeling in non-diabetic heart failure by enhancing myocardial energetics…
Empagliflozin ameliorates adverse ventricular remodeling in non-diabetic heart failure by enhancing myocardial energetics. https://t.co/phvoeqYNRr #JACC https://t.co/W19YJ0yBxL
RT @ValleAlfonso: Empagliflozin ⤵️ adverse cardiac remodeling and HF in a nondiabetic porcine model. Empagliflozin improving myocardial ene…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @ValleAlfonso: Empagliflozin ⤵️ adverse cardiac remodeling and HF in a nondiabetic porcine model. Empagliflozin improving myocardial ene…
RT @yulnunezvill: Empagliflozin Ameliorates Adverse Left Ventricular Remodeling in Nondiabetic Heart Failure by Enhancing Myocardial Energe…
RT @SantosGallegoMD: 1/4 Our original article about the effect of empagliflozin on heart failure in a non-diabetes model just published in…
Enhorabuena @SantosGallegoMD https://t.co/AhBDbr9KVz
RT @JACCJournals: What is the mechanism responsible for the cardiac benefits of empagliflozin? Read more in this week’s #JACC. https://t.co…
RT @ketonemics: Empagliflozin Ameliorates Adverse LV Remodeling in Nondiabetic HF by Enhancing Myocardial Energetics -Empa increases ketone…